Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
종목 코드 CELUW
회사 이름Celularity Inc
상장일May 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
직원 수- -
유형Company Warrant
회계 연도 종료- -
주소170 Park Ave
도시FLORHAM PARK
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호07932
전화19087682170
웹사이트https://celularity.com/
종목 코드 CELUW
상장일May 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음